CD 23 Expression in Plasma Cell Myeloma with t(11;14)
RN Tawil, Q Ahmed, AN Mohamed, G Bentely. Wayne State University School of Medicine, Detroit, MI; Detroit Medical Center, Detroit, MI
Background: CD23 acts as a B cell growth and activation factor, promoting differentiation into plasma cells, as well as regulating IgE synthesis and binding. CD 23 has recently been studied in Plasma Cell Myeloma (PCM), and initial results show that CD 23 is expressed in 10% of these patients. Furthermore, a strong association was observed between CD 23 and abnormalities with chromosome 11 (particularly t(11;14)).
Design: Twenty two bone marrows from PCM patients were selected from a hospital in an urban setting. These patients are male and female, age range between 47 to 71 years old, all with t(11;14) as part of their cytogenetics work up. CD 23 immunostaining was performed on microslides of paraffin-embedded tissue sections from these twenty two patients.
Results: 8/22 cases (36%) expressed CD 23 by immunohistochemistry, and 14/22 (64%) were negative for CD 23 staining.
Conclusions: CD 23 is expressed in 36% of the cases with t(11;14). This corroborates previous studies of the strong association of CD 23 with chromosome 11 abnormalities. Since CD 23 promotes the differentiation of cells into plasma cells, this could be an opportunity for predicting prognosis, or for therapy to utilize the natural machinery of cells, and prevent them from becoming neoplastic plasma cells, especially in the setting of t(11;14).
Tuesday, March 23, 2010 9:30 AM
Poster Session III # 202, Tuesday Morning